CICC: iCarbonX Medical (02158.HK) Continues to Promote AI Medical Business, Maintaining "Outperform Industry" Rating

Zhitong Financial APP learned that Zhongjin issued a research report stating that with the recovery of industry demand and the focus on AI strategy, iMedical Technology (02158.HK) is expected to promote AI solutions in the medical industry and support steady growth in its own performance. The revenue and net profit attributable to the mother for the fiscal year 2026 are expected to remain basically unchanged; introducing performance forecasts for the fiscal year 2027: revenue is expected to be 870 million yuan, and net profit attributable to the mother is expected to be 4.11 million yuan, maintaining an outperform industry rating.